Table 3

Summary of treatment emergent adverse events occurring in at least two participants by treatment group – safety population

CategoryNumber of participants: n (%)
GAI (N=154)GEK (N=157)
Any treatment emergent adverse events71 (46.1)52 (33.1)
Preferred term:
Diarrhea2 (1.3)1 (0.6)
Nausea46 (29.9)36 (22.9)
Vomiting25 (16.2)15 (9.6)
Injection site pain2 (1.3)1 (0.6)
Upper respiratory tract infection2 (1.3)0
Dizziness*2 (1.3)1 (0.6)
Headache8 (5.2)6 (3.8)
  • Results presented have been pooled from both XSGP-301 and XSGP-303 and are presented by treatment.

  • Only preferred terms that resulted in two or more participants experiencing the event within the same treatment are included in this table.

  • Adverse events were coded using Medical Coding Dictionary for Regulatory Activities (MedDRA), V.20.0.

  • *Dizziness is coded under the system organ class ‘nervous system disorders’.

  • GAI, glucagon autoinjector; GEK, glucagon emergency kit.